No insider purchase over the last 90 days. The latest, by Prosky Danny, was filed 24 May 2024.
Analysts rate American Healthcare REIT, Inc. Strong Buy (bullish), based on 16 analysts. Average price target: US$63.69.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2025 · cache
25 of 497 declarations
American Healthcare REIT, Inc. accumulates 412 filings since May 9, 2017, including 192 purchases, 150 grants and 37 option exercises, yet none of the 192 purchases carries an amount in the data. The only quantified operations are 10 sales, worth EUR 4,121,083 with a median of EUR 112,592.
This American real estate company, listed on Nasdaq and valued at USD 11.9 billion, has 19 filers, who hold 0.6% of the capital. Danny Prosky, Director, signs 69, 44 of them purchases, Stefan K.L. Oh (Chief Investment Officer) 61, Jeffrey T. Hanson (Director) 58, Mathieu B. Streiff (Director) 55 and Brian Peay (Chief Financial Officer) 42. The three largest sales are two by Jeffrey T. Hanson, EUR 1,469,675 on December 22, 2025 and EUR 861,153 on November 10, 2025, and one by Brian Peay, EUR 1,115,504 on June 26, 2026.
Volume peaks in 2018 with 126 filings, against 70 in 2017, 50 in 2024 and 47 in 2026. From December 21, 2018 to January 7, 2019, 5 filers bought. The last twelve months hold 50 filings, 8 of them sales and no purchase.
| Fiscal year end | Revenue | Net income | Diluted EPS | Dividend per share | Filing |
|---|---|---|---|---|---|
| Dec 2025 | 2.26 bn USD | 69.8 m USD | 0.42 USD | 1.00 USD | 10-K |
| Dec 2024 | 2.07 bn USD | -37.8 m USD | -0.29 USD | 1.00 USD | 10-K |
| Dec 2023 | 1.87 bn USD | -71.5 m USD | -1.08 USD | 1.00 USD | 10-K |
| Dec 2022 | 1.41 bn USD | -81.3 m USD | -1.24 USD | 1.60 USD | 10-K |
| Dec 2021 | 1.12 bn USD | -47.8 m USD | -0.95 USD | 0.69 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.